Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose and food-effect study of RO6806127 in healthy male volunteers
NL-OMON41129Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing RO6806127 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Pharmacokinetics. Started Jun 2014; status: active, not recruiting.
02
Drugs
RO6806127
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON41129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41129.